Opioid use 12 months following interdisciplinary pain rehabilitation with weaning

Pain Medicine (United States)

Volumn 14, Issue 12, 2013, Pages 1908-1917

  Huffman, Kelly L ^a,b   Sweis, Giries W ^a   Gase, Allison ^a   Scheman, Judith ^a,b   Covington, Edward C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Chronic Non Cancer Pain; Opioid Dependence; Pain Rehabilitation; Therapeutic Opioid Addiction

Indexed keywords

OPIATE;

ADULT; ANALGESIA; ARTICLE; CHRONIC PAIN; DEPRESSION; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; RETROSPECTIVE STUDY; SUBSTANCE ABUSE; TREATMENT OUTCOME;

CHRONIC NON-CANCER PAIN; OPIOID DEPENDENCE; PAIN REHABILITATION; THERAPEUTIC OPIOID ADDICTION;

ADULT; CHRONIC PAIN; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PAIN MANAGEMENT; RETROSPECTIVE STUDIES;

EID: 84890172921     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12201     Document Type: Article

References (62)

1. Cowan DT, Wilson-Barnett J, Griffiths P, Allan LG. A survey of chronic noncancer pain patients prescribed opioid analgesics. Pain Med 2003;4(4):340-351.
2. Saper JR, Lake AE III, Hamel RL, etal. Daily scheduled opioids for intractable head pain: Long-term observations of a treatment program. Neurology 2004;62(10):1687-1694.
3. Ballantyne JC, LaForge KS. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 2007;129(3):235-255.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edition, text revision); 2000.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition; 2013.
6. Boscarino JA, Rukstalis MR, Hoffman SN, etal. Prevalence of prescription opioid-use disorder among chronic pain patients: Comparison of the DSM-5 vs. DSM-4 diagnostic criteria. J Addict Dis 2011;30(3):185-194.
7. Højsted J, Sjøgren P. Addiction to opioids in chronic pain patients: A literature review. Eur J Pain 2007;11(5):490-518.
8. Sweis G, Huffman K, Shella E, Scheman J. Longitudinal treatment outcomes of patients with comorbid chronic pain and substance dependence within a multidisciplinary chronic pain program. J Pain 2012;13(4):S107.
9. Covington E, Kotz M. Pain reduction with opioid elimination. Pain Med 2002;3(2):183.
10. Morasco BJ, Gritzner S, Lewis L, etal. Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder. Pain 2011;152(3):488-497.
11. Kennedy JA, Crowley TJ. Chronic pain and substance abuse: A pilot study of opioid maintenance. J Subst Abuse Treat 1990;7(4):233-238.
12. Magura S, Rosenblum A. Leaving methadone treatment: Lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001;68(1):62-74.
13. Weiss RD, Potter JS, Fiellin DA, etal. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Arch Gen Psychiatry 2011;68(12):1238-1246.
14. Gossop M, Stewart D, Browne N, Marsden J. Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: Protective effect of coping responses. Addiction 2002;97(10):1259-1267.
15. Gossop M, Green L, Phillips G, Bradley B. Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry 1989;154:348-353.
16. Chutuape MA, Jasinski DR, Fingerhood MI, Stitzer ML. One-, three-, and six-month outcomes after brief inpatient opioid detoxification. Am J Drug Alcohol Abuse 2001;27(1):19-44.
17. Caldeiro RM, Malte CA, Calsyn DA, etal. The association of persistent pain with out-patient addiction treatment outcomes and service utilization. Addiction 2008;103(12):1996-2005.
18. Larson MJ, Paasche-Orlow M, Cheng DM, etal. Persistent pain is associated with substance use after detoxification: A prospective cohort analysis. Addiction 2007;102(5):752-760.
19. Rosenblum A, Joseph H, Fong C, etal. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003;289(18):2370-2378.
20. Jamison RN, Kauffman J, Katz NP. Characteristics of methadone maintenance patients with chronic pain. J Pain Symptom Manage 2000;19(1):53-62.
21. Shiffman S, Waters AJ. Negative affect and smoking lapses: A prospective analysis. J Consult Clin Psychol 2004;72(2):192-201.
22. Wheeler RA, Twining RC, Jones JL, etal. Behavioral and electrophysiological indices of negative affect predict cocaine self-administration. Neuron 2008;57(5):774-785.
23. Curran GM, Flynn HA, Kirchner J, Booth BM. Depression after alcohol treatment as a risk factor for relapse among male veterans. J Subst Abuse Treat 2000;19(3):259-265.
24. Ludwig AM, Wikler A. "Craving" and relapse to drink. Q J Stud Alcohol 1974;35(1 pt A):108-130.
25. Hartz DT, Frederick-Osborne SL, Galloway GP. Craving predicts use during treatment for methamphetamine dependence: A prospective, repeated-measures, within-subject analysis. Drug Alcohol Depend 2001;63(3):269-276.
26. Sinha R, O'Malley SS. Craving for alcohol: Findings from the clinic and the laboratory. Alcohol Alcohol 1999;34(2):223-230.
27. Currie SR, Hodgins DC, Crabtree A, Jacobi J, Armstrong S. Outcome from integrated pain management treatment for recovering substance abusers. J Pain 2003;4(2):91-100.
28. Chou R, Fanciullo GJ, Fine PG, etal. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-130.
29. Michna E, Ross EL, Hynes WL, etal. Predicting aberrant drug behavior in patients treated for chronic pain: Importance of abuse history. J Pain Symptom Manage 2004;28(3):250-258.
30. Wasan AD, Butler SF, Budman SH, etal. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain 2007;23(4):307-315.
31. American Academy of Pain Medicine. the American Pain Society and the American Society of Addition Medicine. Definitions related to the use of opioids for the treatment of pain. WMJ 2001;100(5):28-29.
32. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003;70(suppl 2):S39-47.
33. Mendelson J, Jones RT, Welm S, etal. Buprenorphine and naloxone combinations: The effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl) 1999;141(1):37-46.
34. Cephalon. Actiq package insert. 2011. Available at: http://www.actiq.com/pdf/actiq_package_insert_%204_5_07.pdf (accessed March 2012).
35. Cephalon. Fentora package insert. 2011. Available at: http://www.fentora.com/pdfs/pdf100_prescribing_info.pdf (accessed March 2012).
36. Hospira. Talwin package insert. 2011. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3107d8eb-ebe8-4114-9db0-2d278612f186 (accessed March 2012).
37. Purdue Pharma. Oxycontin. 2012. Available at: http://www.purduepharma.com/pi/prescription/oxycontin.pdf (accessed March 2012).
38. Reckitt Benckiser Pharmaceuticals Inc. Buprenex (Buprenorphrine Hydrochloride). 2005. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b086772e-d15a-4d13-b1a2-38bfbde1f18c (accessed March 2012).
39. Janssen Pharmaceuticals. Nyucenta-Equianlgesic dosing. 2012.
40. De Conno F, Groff L, Brunelli C, etal. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996;14(10):2836-2842.
41. Doyle D, Woodruff R. The IAHCP Manual of Palliative Care, 2nd edition. 2008. Available at: http://hospicecare.com/uploads/2011/9/iahpc-manual-08.pdf (accessed March 2012).
42. Agency Medical Directors Group. Intragency Guideline on Opioid Dosing for Chronic Non-cancer Pain: An educational aid to improve care and safety with opioid therapy. 2010. Available at: http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf (accessed March 2012).
43. Joint Pharmacy and Therapeutics Committee of Mercy Medical Center and St. Luke's Hospital. Equianalgesic dose of opioid drugs. 2004. Available at: http://www.crjointpt.com/library/opioid.pdf (accessed March 2012).
44. Moses S. Narcotic Analgesics: Family Practice Notebook. 2009. Available at: http://www.fpnotebook.com/Pharm/Analgesic/NrctcAnlgsc.htm (accessed March 2012).
45. US Veteran's Administration and Stanford University Medical School. End of Life Curriculum Project. 2012. Available at: http://endoflife.stanford.edu/M11_pain_control/doses_m01.html (accessed March 2012).
46. Hartrick CT, Kovan JP, Shapiro S. The numeric rating scale for clinical pain measurement: A ratio measure? Pain Pract 2003;3(4):310-316.
47. Breivik EK, Björnsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain 2000;16(1):22-28.
48. Kremer E, Atkinson JH, Ignelzi RJ. Measurement of pain: Patient preference does not confound pain measurement. Pain 1981;10(2):241-248.
49. Seymour RA. The use of pain scales in assessing the efficacy of analgesics in post-operative dental pain. Eur J Clin Pharmacol 1982;23(5):441-444.
50. Lovibond SH, Lovibond PF. The DASS: Manual for the Depression Anxiety Stress Scales 2nd edition. Sydney: Psychology Foundation; 1995.
51. Antony MM, Bieling PJ, Cox BJ, Enns MW, Swinson RP. Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales in clinical groups and a community sample. Psychol Assess 1998;10(2):176-181.
52. Page AC, Hooke GR, Morrison DL. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in depressed clinical samples. Br J Clin Psychol 2007;46(Pt 3):283-297.
53. Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav Res Methods 2009;41(4):1149-1160.
54. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39(2):175-191.
55. Cohen J. A power primer. Psychol Bull 1992;112(1):155-159.
56. Michael R, Sorrell WF. The effect of depression and anxiety on the success of multidisciplinary treatment of chronic resistant myofascial pain. J Musculoskelet Pain 2003;11:17-20.
57. Teh CF, Zaslavsky AM, Reynolds CF, Cleary PD. Effect of depression treatment on chronic pain outcomes. Psychosom Med 2010;72(1):61-67.
58. Riley J, Robinson M, Wise E, etal. Predicting treatment compliance following facial pain evaluation. Cranio 1999;17(1):9-16.
59. Moore BA, Fiellin DA, Barry DT, etal. Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients. J Gen Intern Med 2007;22(4):527-530.
60. Sigmon SC. Characterizing the emerging population of prescription opioid abusers. Am J Addict 2006;15(3):208-212.
61. World Health Organization. ICD-10 Classifications of mental and behavioral disorder: Clinical descriptions and diagnostic guidelines. 1992.
62. Morasco BJ, Duckart JP, Carr TP, Deyo RA, Dobscha SK. Clinical Characteristics of Veterans Prescribed High Doses of Opioid Medications for Chronic Non-Cancer Pain. Pain 2010;151(3):625-632.